Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses.
Data Brief
; 38: 107352, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-34584913
ABSTRACT
Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levofloxacin through a meta-analysis were reported in paper 'Clinical benefits and cost-effectiveness of moxifloxacin as initial treatment for community-acquired pneumonia a meta-analysis and economic evaluation'. In this dataset, we aimed at investigating more clinical endpoints comparing the efficacy and safety of moxifloxacin and levofloxacin in the treatment of CAP.
Texto completo:
1
Temas:
ECOS
/
Avaliacao_economica
Bases de dados:
MEDLINE
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Data Brief
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China